THYROCARE TECHNOLOGIES
|
|
BOM : 539871     NSE : THYROCARE     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Good [Stock is Cheap] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Downward Pledged Shares : High [>50%] |
Mar 22,2023 |
Price(EOD): ₹ 443.30
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Hospital & Healthcare Services |
MCap: ₹ 2,345.06 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
THYROCARE TECHNOLOGIES | -4.7% | -6.5% | -41.1% |
APOLLO HOSPITALS ENTERPRISE | -1% | -7.2% | -10.4% |
MAX HEALTHCARE INSTITUTE | 0.5% | 8.8% | 37.7% |
FORTIS HEALTHCARE | -4.5% | -9% | -1.8% |
DR LAL PATHLABS | -2% | -6.8% | -33.2% |
NARAYANA HRUDAYALAYA | -3.7% | 6.5% | 12.3% |
KRISHNA INSTITUTE OF MEDICAL SCIENCES | -1% | -3.9% | -0.5% |
ASTER DM HEALTHCARE | 4% | 3.4% | 35.5% |
RAINBOW CHILDRENS MEDICARE | 1.1% | -0.7% | NA |
FUNDAMENTAL ANALYSIS OF THYROCARE TECHNOLOGIES
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF THYROCARE TECHNOLOGIES
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
32.71
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 71.73 Cr
[Latest Qtr - Dec2022 - Consolidated Results ] 4.49
P/B Calculated based on Book Value of Rs 523.13 Cr
[Latest Year - Mar2022 - Consolidated Results ] 4.5
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 521.35 Cr
[Latest Qtr - Dec2022 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
-32% -23% -33% |
SHARE PRICE MOMENTUM OF THYROCARE TECHNOLOGIES
THYROCARE TECHNOLOGIES vs SENSEX
DEBT OF THYROCARE TECHNOLOGIES
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2022 2021 2020 Avg_3yrs |
0 0 0 - |
0 0 0.01 - |
[Last Annual Data : Mar2022]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF THYROCARE TECHNOLOGIES
Pledged Promoter Shares |
100 % | |
---|---|---|
As on : Dec2022 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF THYROCARE TECHNOLOGIES
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-5.14% -11.78% -18.21% -7.31% |
9.05% -24.29% -33.46% -34.52% |
QtrlyTrend |
-6 | |
Latest Qtr: Dec2022 | ||
Quarterly Result Analysis → |
THYROCARE TECHNOLOGIES related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE 500 | 1% | -3.6% | -1.7% |
S&P BSE ALLCAP | 0.9% | -3.6% | -1.7% |
S&P BSE HEALTHCARE | 0.5% | -2.8% | -10.9% |
S&P BSE 250 SMALLCAP | 0.2% | -2.6% | -0.9% |
S&P BSE SMALL CAP | 0% | -3.1% | -1.9% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY 500 | 1% | -3.6% | -1.8% |
NIFTY500 MULTICAP 50:25:25 | 0.7% | -3.3% | -1.4% |
NIFTY MID SMALL400 | 0.2% | -2.6% | 1.5% |
NIFTY SMALLCAP250 | 0.1% | -3.2% | -4.4% |
You may also like the below Video Courses
FAQ about THYROCARE TECHNOLOGIES
Is THYROCARE TECHNOLOGIES good for long term investment?
As on Mar 22,2023, the Fundamentals of THYROCARE TECHNOLOGIES look Strong and hence it may be good for long term investment! See Financial Performance of THYROCARE TECHNOLOGIES . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is THYROCARE TECHNOLOGIES UnderValued or OverValued?
As on Mar 22,2023, THYROCARE TECHNOLOGIES is Under Valued based on the estimates of intrinsic value and hence may be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of THYROCARE TECHNOLOGIES ?
As on Mar 22,2023, the Intrinsic Value of THYROCARE TECHNOLOGIES is Rs. 652.65 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 652.65
Fair Value [Median EV / Sales Model] : Rs. 578.72
Fair Value [Median Price / Sales Model] : Rs. 665.87
Estimated Median Fair Value of THYROCARE TECHNOLOGIES : Rs. 652.65
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.
Is THYROCARE TECHNOLOGIES trading at a Premium or Discount?
As on Mar 22,2023, THYROCARE TECHNOLOGIES is trading at a Discount of -32% based on the estimates of Median Intrinsic Value!